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Abstract
The objective of the present study was to investigate vascular endothelial growth factor A
(VEGFA) isoform regulation of cell fate decisions of spermatogonial stem cells (SSC) in vivo.
The expression pattern and cell-specific distribution of VEGF isoforms, receptors, and
coreceptors during testis development postnatal d 1–180 suggest a nonvascular function for
VEGF regulation of early germ cell homeostasis. Populations of undifferentiated spermatogonia
present shortly after birth were positive for VEGF receptor activation as demonstrated by
immunohistochemical analysis. Thus, we hypothesized that proangiogenic isoforms of VEGF
(VEGFA164) stimulate SSC self-renewal, whereas antiangiogenic isoforms of VEGF
(VEGFA165b) induce differentiation of SSC. To test this hypothesis, we used transplantation to
assay the stem cell activity of SSC obtained from neonatal mice treated daily from postnatal d 3–
5 with 1) vehicle, 2) VEGFA164, 3) VEGFA165b, 4) IgG control, 5) anti-VEGFA164, and 6) antiVEGFA165b. SSC transplantation analysis demonstrated that VEGFA164 supports self-renewal,
whereas VEGFA165b stimulates differentiation of mouse SSC in vivo. Gene expression analysis

of SSC-associated factors and morphometric analysis of germ cell populations confirmed the
effects of treatment on modulating the biological activity of SSC. These findings indicate a
nonvascular role for VEGF in testis development and suggest that a delicate balance between
VEGFA164 and VEGFA165b isoforms orchestrates the cell fate decisions of SSC. Future in vivo
and in vitro experimentation will focus on elucidating the mechanisms by which VEGFA
isoforms regulate SSC homeostasis.
Spermatogonial stem cells (SSC) reside in the seminiferous tubules of the testis and are the only
adult stem cell population capable of transmitting genes to offspring. SSC and their ability to
self-renew ensure maintenance of fertility throughout the lifespan of the male, whereas SSC
differentiation functions to provide germ cell progeny leading to the production of spermatozoa.
The process, spermatogenesis, is one of the most productive biological processes in mammals,
leading to a virtually unlimited supply of spermatozoa throughout the lifespan of an adult male.
Thus, the balance between SSC self-renewal and differentiation, or homeostasis, is critical for
male fertility.
In rodents, gonocytes are the first male-specific germ cells present in the testis during fetal and
postnatal development (1), and these cells undergo mitotic arrest late in gestation until shortly
after birth when they resume mitosis around postnatal d 1.5 (P1.5) to P3 (2). Gonocytes
ultimately give rise to the SSC pool but must first migrate from the center of the testicular cords
to the basement membrane, an event initiated around P3 (3). During this period of migration,
gonocytes resume mitosis (4, 5) and undergo one of three fates: some mature into SSC, some
differentiate and initiate spermatogenesis, whereas the remainder degenerate (4–6). In vivo
transplantation studies indicate that testicular germ cells obtained from P0–P3 mice can colonize
recipient testes but do not initiate self-renewal or establish donor-derived spermatogenesis (1, 6).
In contrast, germ cells collected from P4–P5 testes generate large areas of donor-derived
spermatogenesis in recipients after colonization (7), indicating the presence of robust stem cell
activity and SSC formation.
SSC reside near the basement membrane of seminiferous tubules and are intimately associated
with somatic cells that include Sertoli cells, peritubular myoid cells, and Leydig cells.
Accordingly, the environmental cues influencing the cell fate decisions of SSC during this
critical period of germ cell development remain unclear, but it is thought that intrinsic and
extrinsic factors produced by the stem cell niche may function to modulate SSC homeostasis in
vivo (8). For example, glial cell line-derived neurotrophic factor (GDNF) produced by Sertoli
cells functions to directly regulate the maintenance and self-renewal of SSC (9), a result
confirmed by transplantation (10). However, identification of the additional factors regulating
SSC remains difficult because no bona fide SSC markers exist, and the only way stem cell
activity can be determined is with use of the transplantation assay (11).
Several reports suggest that blood vessels in the interstitial compartment of the testis constitute a
niche microenvironment for undifferentiated spermatogonia and SSC populations in the postnatal
testis (12–14). Along those lines, angiogenic factors such as vascular endothelial growth factor A
(VEGFA) and its receptors have been implicated in nonvascular roles such as directing testis
morphogenesis in mice (15, 16) and regulating the biological activity of undifferentiated germ
cells in bovine testis tissue (17) in a manner independent of angiogenesis (17, 18). These studies

have yet to 1) determine the function of VEGF family molecules on regulating the cell fate
decisions of SSC and 2) differentiate between the effects of proangiogenic isoforms (VEGFxxx)
and antiangiogenic (VEGFxxxb) isoforms. Alternative splicing of VEGFA yields multiple
proangiogenic isoforms (VEGFA111, VEGFA121, VEGFA145, VEGFA162, VEGFA165, VEGFA183,
and VEGFA206) and multiple antiangiogenic (VEGFA121b, VEGFA145b, VEGFA165b, VEGFA
183b, and VEGFA189b) isoforms (19). VEGFA165 (VEGFA164 in mice) and VEGFA165b are the
most prevalent and biologically active splice variants in humans, respectively. The VEGFA
splice variants are generated by proximal and distal splice sites in exon 8 of the VEGFA gene
(19). Moreover, these families of VEGFA isoforms have diverse functions in vivo: VEGFA165
stimulates endothelial cell proliferation, migration, and survival (20–22), whereas VEGFA165b
isoforms inhibit VEGFA165-induced signal transduction and physiological outcomes (23–29).
Three VEGFA receptors (VEGFR) have been identified called FLT1 (VEGFR1), KDR
(VEGFR2), and VEGFR3 with kinase insert domain receptor (KDR) eliciting the greatest
intracellular signaling for promoting cell proliferation, whereas fms-related tyrosine kinase 1
(FLT1) activation stimulates cell migration; the role of VEGFR3 is presently unknown. In
addition to multiple receptors, VEGFA isoforms interact with two soluble cofactors, neuropilin 1
(NRP1) and NRP2, that can either facilitate or suppress VEGFA isoform-receptor interaction and
subsequent signaling. Nevertheless, signal transduction events triggered by VEGFA family
members within nonvascular targets are poorly understood, especially in the postnatal testis.
The objective of the present study was to evaluate the role of VEGFA isoform signaling in vivo
in regard to regulating the cell fate decisions of SSC. We hypothesized that proangiogenic
isoforms of VEGFA (VEGFA164) stimulate SSC self-renewal, whereas antiangiogenic isoforms
(VEGFA165b) induce differentiation of SSC. To test this hypothesis, we used the functional SSC
transplantation technique to assay the effects of VEGFA isoform treatment combinations on the
stem cell activity of SSC in vivo.

Materials and Methods
Animal care and treatments
All animal experiments were approved by Washington State University Animal Care and Use
committees and were conducted in accordance with the Guiding Principles for the Care and Use
of Research Animals of the National Institutes of Health. Animals were housed in a standard
animal facility and provided ad libitum access to food and water. Rosa26 (stock no. 002192) and
C57BL/6 (stock no. 000664) mice were obtained from The Jackson Laboratory (Bar Harbor,
ME).

Quantitative real-time RT-PCR (qRT-PCR) analysis
qRT-PCR was conducted as previously described (17) using an iCycler iQ (Bio-Rad, Hercules,
CA) detection system. Total RNA was prepared from C57BL/6 testis tissue using the TRIzol
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. RNA concentration
and purity were determined using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific, Schwerte, Germany), and only samples with a 260/280 ratio of at least 1.8 were used
for qRT-PCR analysis. A list and description of TaqMan probe sets used for gene expression in

the current study are provided (Table 1). Ribosomal protein S2 was used as a normalization
reference. Relative quantification of mRNA levels was calculated using the Q-Gene method (30).
At least three donors were used for each age and treatment (n ≥ 3).

Immunohistochemistry of VEGF ligands and receptors
Immunohistochemistry was performed on paraffin-embedded testis tissue sections (5 μm
thickness) obtained from normal C57BL/6 mice using the avidin-biotin complex method and
sodium citrate antigen retrieval (10 mm sodium citrate, pH 6.0), as described (31). A list of
affinity-purified primary antibodies (diluted in 10% normal serum, pH 7.4) is provided (Table 2).
Immunoreactivity was detected using 3,3′-diaminobenzidine, and sections were counterstained
with hematoxylin. As a negative control, serial sections were processed without primary
antibody. At least three donors were used for each age and antigen evaluated (n ≥ 3).

Analysis of VEGFR activation (phosphorylation) in vivo
Testis tissue obtained from neonatal and postnatal C57BL/6 mice was detunicated, fixed in 4%
paraformaldehyde (in 10 mm PBS) at 4 C for 8 h followed by paraffin embedding and sectioning
(5 μm thickness). After standard processing, heat-induced epitope retrieval with Tris-EDTA
buffer [10 mm Tris Base, 1 mm EDTA solution, 0.05% Tween 20 (pH 9.0)] was used to unmask
antigens before quenching endogenous peroxidase activity. After several washes in PBS, slides
were blocked (10% normal serum vol/vol in PBS) for 30 min, incubated with affinity-purified
antibodies to detect endogenous VEGFR signaling (Abcam, Cambridge, MA) for 12 h at 4 C.
Briefly, sections were incubated with 1) rabbit polyclonal to the kinase active domain of human
FLT1 (1:150; ab62183) phosphorylated at tyrosine 1333 (V-L-YP-S-T) (32), 2) rabbit polyclonal
to activated catalytic domain of human KDR (1:150; ab63405) phosphorylated at tyrosine 1054
(d-I-YP-K-D) (33–35), and 3) rabbit polyclonal to activated human NRP1 (1:100; ab71766)
phosphorylated at threonine T916 (LNTQS) (36, 37). After a series of washes, sections were
processed with a biotinylated goat antirabbit secondary antibody for 60 min and then washed
again and incubated with streptavidin-horseradish peroxidase substrate for 20 min at 25 C.
Immunoreactivity was detected after a 2-min incubation in 3,3′-diaminobenzidine, and sections
were lightly counterstained with hematoxylin. Sections of developing mouse kidney were
processed as a positive control (data not shown). A negative control, serial sections were
processed without primary antibody. Four donors were used for each age and antigen evaluated
(n = 4).

Neonatal mice treatment
Neonatal mice were treated according to the methodology described by Gerber et al. (38), with
minor modifications. Fifty-microliter glass syringes (Hamilton, Reno, NV) were used to
administer all ip treatments (10 μl each). Briefly, A 30-gauge needle was inserted approximately
2–3 mm (commensurate with body wall thickness from P3–P5) into the lower right quadrant of
the abdominal cavity at a 20° angle (to avoid the cecum and urinary bladder) and ensure rapid
delivery of our various treatments. Neonatal mice (P3–P5) received a single, daily ip injection of
vehicle (10 mm PBS plus 0.1% BSA), VEGFA164 (500 ng, wt/vol; R&D Systems, Minneapolis,
MN), or VEGFA165b (500 ng, wt/vol; R&D Systems) on P3, P4, and P5, respectively. To

evaluate the effect of blocking VEGFA isoforms, we also treated neonatal mice with affinitypurified antibodies against VEGFA164 (1 μg, wt/vol; Santa Cruz Biotechnology, Santa Cruz,
CA), VEGFA165b (1 μg, wt/vol; Abcam), or rabbit IgG (1 μg, wt/vol; Vector Labortories,
Burlingame, CA) within a similar timeframe. After treatment, Rosa26 mice were killed at P8 and
P22, and testes were processed to obtain donor SSC for transplantation. In addition, we evaluated
testicular growth and kinetics of germ and Sertoli cell proliferation in a group of C57BL/6 mice
killed at 3 d (P8) and 17 d (P22) after treatment. Testes were also harvested from a subset of
C57BL/6 mice at P8, P12, and P22 to determine the effect of treatments on the mRNA
expression of factors associated with the biological activity of SSC.

Preparation of donor germ cells
Rosa26 donor testes were enzymatically digested as described by McLean (11), with minor
modifications. Briefly, testis tissue was transferred to a dish containing digestion medium, which
consisted of 0.18 mg/ml trypsin (GibcoBRL, Bethesda, MD) 0.16 mg/ml collagenase type IV
(Sigma Chemical Co., St. Louis, MO), and 0.6 mg/ml deoxyribonuclease (Sigma) in MEM αmedium (pH 7.4) and incubated for 10 min at 37 C. After incubation and addition of FBS (10%
vol/vol), testis tissue digests were dispersed by gentle pipetting, and the resulting cell suspension
was centrifuged at 600 × g for 7 min at 4 C. After several washes, donor cells were resuspended
in MEM containing 0.03% trypan blue (GibcoBRL) to obtain spermatogonial stem cells for
transplantation at a concentration of 107 cells/ml.

Germ cell transplantation and analysis of recipient testes
To determine stem cell activity, approximately 7.8 × 104 donor cells were transplanted into
seminiferous tubules of busulfan-treated, immunologically compatible 129SvCP × C57BL/6 F1
hybrid recipient mice. When the infused volume deviated from 7 μl, the actual cell number
injected was used for colonization efficiency calculations. Recipient mice were killed 8 wk after
transplantation, and the colonization efficiency of Rosa26 SSC were determined by counting the
number and length of blue colonies after staining with 5-bromo-4-chloro-3-indoyl β-dgalactoside.

Statistical analysis
All datasets are presented as the mean ± sem, and differences between ages and treatment groups
were considered significant at P < 0.05. The effect of treatments on testis size, germ cell number,
expression of SSC niche-associated factors, and stem cell activity were analyzed using a oneway ANOVA, and pairwise comparisons were evaluated with a Newman-Keuls multiple-range
test. The effect of age on gene expression during testis development was also evaluated using
ANOVA, and homogeneity of variance was determined using the Bartlett's test. Heteroscedastic
datasets were analyzed using the Kruskal-Wallis test, and comparisons between groups were
evaluated using the Dunn's multiple-comparison post hoc test (P < 0.05).

Results

Gene expression of VEGF family molecules during mouse testis development
We assayed the expression of VEGF isoforms, receptors, and coreceptors during mouse testis
development. The expression of each gene at each age was compared with the expression at P0
(day of birth), which was set at 1.0. This provides an accurate evaluation of gene expression
during testis development for interpretation. The mouse ages selected for gene expression
analysis coincided with the age when germ cell-initiated biological events occur, including
migration and differentiation. Similarly, specific time points for somatic proliferation and
differentiation were included to develop a complete understanding of the dynamics of testis
development associated with VEGF signaling. Vegfa isoform expression was highest during
early testis development until declining after P20 to P180 (Fig. 1A). Flt1 (vegfr1) expression was
highest at birth and declined until P8, followed by an increase in expression at P10–P12 and then
declining at P14 and remaining at this level throughout adulthood. Kdr (vegfr2) expression was
highest during P1–P6, intermediate during P8–P20, and lowest from P20 throughout adulthood
(Fig. 1C). Nrp1 was expressed at a stable level from birth until P20, followed by a 2- and 4-fold
decrease at P35 and P105 that remained constant through P180 (Fig. 1D). Nrp2 was expressed in
the neonatal testis from birth until P10 with a sharp increase at P12. Nrp2 expression
subsequently declined 2-, 4-, and 6-fold from P20 until P35, P105, and P180, respectively,
compared with its peak at P12 (Fig. 1E). The expression of VEGFA family molecules in the
testis is present during the neonatal period concurrent with SSC formation and proliferation. The
VEGFA primers did not distinguish between splice variant isoforms; thus, we conducted
immunohistochemistry with antibodies specific for VEGFA164 and VEGFA165b, the two most
biologically active isoforms.

Protein expression of VEGF family molecules during mouse testis development
To determine the specific cells that express the VEGF isoforms, receptors, and coreceptors, we
assayed with immunohistochemistry the expression of these proteins daily from birth until P22 in
mouse testes. SSC form at P3 and initiate differentiation and proliferation between P5 and P8
(7), so we focused on precise analysis of VEGFA isoform expression in specific testicular cells
at these ages. Comparison with negative controls (omission of primary antibody, Fig. 2, A–C)
demonstrates that VEGFA164 expression was present in gonocytes and to a lesser degree in
Sertoli cells at P3 (Fig. 2D) until P5 (Fig. 2E). From P5–P8, the expression of VEGFA164 was
mainly in Sertoli cells (Fig. 2, E and F) with a marked reduction in germ cell expression
compared with the first 5 d of life. This age coincides with gonocyte migration and formation of
the SSC population. In contrast, VEGFA165b was more heterogeneous in expression during the
P3–P5 period, being restricted to a distinct subset of gonocyte, undifferentiated spermatogonia,
and Sertoli cell populations in the seminiferous tubules (Fig. 2, G–I). VEGFA165b was also
present in primary spermatocytes and round spermatids at P20 (Supplemental Fig. 1G, published
on The Endocrine Society's Journals Online web site at http://endo.endojournals.org).
FLT1 (VEGFR1) and KDR (VEGFR2) were remarkably similar in expression pattern within cell
types that were positive for each protein. As can be seen in Supplemental Fig. 1, A–D, FLT1 and
KDR were expressed in gonocytes at P3, spermatogonia at P5, and Sertoli cells. NRP1 was
expressed by gonocytes and Sertoli cells at P3 (Supplemental Fig. 1E) and primarily localized to
undifferentiated spermatogonia at P5 (Supplemental Fig. 1F) with continued expression in

spermatogonia from P6–P20. FLT1 and KDR were also detected within testicular interstitial
somatic cells throughout development, evidenced by uniform localization in populations of
Leydig cells and spasmodic expression in lymphatic endothelial cells (Supplemental Fig. 1, A–
D).

VEGFR signaling is active in germ and somatic cells during mouse testis
development in vivo
VEGFA164/165b isoforms primarily elicit their effects on cell function after binding to KDR and
FLT1, although signal transduction is more pronounced after KDR binding compared with FLT
binding. Activation of KDR occurs via two independent pathways: VEGFA164/165b binds directly
to KDR or VEGFA isoforms bind directly to NRP1, which presents the ligand to KDR after
heterodimerization. Thus, after characterizing the patterns and cell-specific aspects of VEGF
ligand and receptor mRNA and protein expression in vivo, we wanted to determine the specific
cell types affected by VEGF signaling during neonatal testis development. To accomplish this
goal, we used immunohistochemical analysis to detect the phosphorylation-specific expression
of p-FLT1Y1333, p-KDRY1054, and p-NRP1T916 in germ and somatic cells during gonocyte
maturation (P1–P5), SSC formation (P5–P6), and the first round of SSC expansion and selfrenewal in vivo (P8–P14).
Endogenous FLT1 signaling detected by positive staining for p-FLT1Y1333 (the kinase active
domain) was mainly localized to gonocytes at P1, but heterogeneous low-grade expression was
also detected in Sertoli cells and interstitial Leydig cells (Supplemental Fig. 2D). When
compared with P1, the activation of FLT1 signaling was greatly increased in somatic cells based
on increased staining intensity for p-FLT1Y1333 in Sertoli cells, Leydig cells, and lymphatic
endothelial cells at P3. Interestingly, activated FLT1 signaling was restricted to a subset of
pericentrically localized gonocytes in the seminiferous tubules and a few lymphatic endothelial
and Leydig cells from P3–P6 (Supplemental Fig. 2E). In contrast, the expression of p-FLT1Y1333
diminished in germ cells after gonocyte migration to the basement membrane and subsequent
conversion into undifferentiated spermatogonia during P6–P8. Activation of FLT1 in germ cells
did not occur after P8 until approximately P20 when positive staining for p-FLT1Y1333 was
detected in type-B spermatogonia and preleptotene primary spermatocytes (Supplemental Fig.
2F). Thus, FLT1 signaling appears to be related to survival and migration of gonocytes and other
differentiated germ cell types.
In contrast to FLT1, detection of KDR signaling in the testis after birth was variable. At P1, very
few gonocytes expressed p-KDRY1054 (Supplemental Fig. 2G); however, this proportion
increased by P3 (Supplemental Fig. 2H), the time period in which gonocytes resume
proliferation. Sertoli cells from P1–P3 are positive for p-KDRY1054; however, by P5, Sertoli cells
are negative, whereas undifferentiated spermatogonia are positive for p-KDRY1054 (Supplemental
Fig. 2H). Activation of KDR in Sertoli cells occurs around P6 and remains strong until P8, when
spermatogonia lose the positive signal for p-KDRY1054.
NRP1 signaling appears to be minimal within the seminiferous tubules after birth based on low
staining intensity for p-NRP1T916 in gonocytes and Sertoli cells (Supplemental Fig. 2, J and K).
Immunohistochemical analysis demonstrated that NRP1 activation in gonocytes, Sertoli cells,

and undifferentiated spermatogonia occurs from P3–P8 (Supplemental Fig. 2K) and then
declines until adulthood. NRP1 activation is rare by P14 and was observed in only approximately
5–6% of tubule cross-sections evaluated (one of 18), being localized and restricted to single
undifferentiated spermatogonia in tubule cross-sections (Supplemental Fig. 2L).

VEGF isoforms regulate testis development and the biological activity of
undifferentiated germ cells in vivo
After assaying the expression pattern of VEGF family molecules and evaluating the timeline for
VEGFR activation during neonatal testis development, we sought to determine the role of
specific VEGF isoforms in regulating SSC cell fate decisions. To accomplish this objective, we
used the approach of treating neonatal (P3–P5) mice in vivo using two experimental paradigms
(Fig. 3A). Briefly, mice received daily ip injections of 1) control (vehicle alone; 10 mm PBS plus
0.1% BSA), VEGFA164 (500 ng, wt/vol), or VEGFA165b (500 ng, wt/vol) and 2) IgG control (1
μg, wt/vol), anti-VEGFA164 (1 μg, wt/vol), or anti-VEGFA165b (1 μg, wt/vol). It is known that a
decline in testis weight indicates impaired cellular development or disruption of spermatogenesis
in the postnatal testis. Thus after killing, body weight and paired testes weights were recorded at
P8 and P22. When compared with vehicle alone, no difference in testis weight was detected at P8
after VEGFA164 or VEGFA165b treatment (Fig. 3B). However, we observed a significant
reduction (P = 0.005) in testis weight when killed at P22 in mice treated with VEGFA165b from
P3–P5 when compared with testis weights in control or VEGFA164 treatment groups. Moreover,
inhibiting the biological activity of VEGFA164 with anti-VEGFA164 significantly decreased (P =
0.0242) testis weight at P8, when compared with IgG control or the anti-VEGFA165b treatment
groups, respectively (Fig 3C). No differences in testis weight were detected when mice were
evaluated at P22 (Fig 3C). Thus, VEGFA isoforms are likely important regulators of neonatal
testis development in vivo.
We also evaluated our treatment approach on the kinetics of germ and Sertoli cell proliferation
and survival in a subset of mice by counting these cells at each biological endpoint. Regardless
of treatment, no differences in Sertoli cell number were detected at P8–P22 (data not shown). We
assayed the number of germ cells in testes from treated and control animals to determine whether
treatment altered the initiation or pace of germ cell differentiation. Immunohistochemistry with
an antibody for the germ cell-specific marker DEAD (Asp-Glu-Ala-Asp) box polypeptide 4
(DDX4) was used to count germ cells. DDX4 is expressed by all germ cells in developing testes
providing a useful marker to determine whether changes in the SSC or undifferentiated
spermatogonia population lead to changes in meiotic germ cells. Treating mice with VEGFA165b
significantly increased the number of germ cells (DDX4+ cells) present at P8, but not P22, when
compared with controls (Fig. 4A); a correlated increase in seminiferous tubule diameter was also
observed (data not shown). Similarly, VEGFA165b treatment significantly increased the number
of spermatogonia localized at the basement membrane at P8 (Fig. 4C), whereas blocking
VEGFA165b activity with an antibody resulted in germ cell loss at P8 (Fig. 4D), suggesting a
cytoprotective role for VEGFA165b. Thus, a balance with respect to the actions of VEGFA
isoforms may be required to support the proliferation, maturation, and survival of
undifferentiated spermatogonia. Light micrographs demonstrating immunohistochemical
analysis of DDX+ cells in P8 and P22 testis tissue after in vivo treatment are provided (Fig. 4, E
and F).

After treatments, mice were killed at P8, P12, and P22 and evaluated for several factors
associated with SSC self-renewal (bcl6b and nanos2) and early differentiation (neurog3) with the
use of qRT-PCR. TaqMan PCR assays were used to determine the in vivo effect of VEGFA
isoform treatments on the mRNA expression of bcl6b, nanos2, and neurog3 in developing mouse
testis tissue. Regardless of treatment, no significant differences were observed in bcl6b, nanos2,
or neurog3 expression at P8 or P12 (Fig. 5, A–F). However, VEGFA164 and VEGFA165b
treatments resulted in a significant decrease of bcl6b and neurog3 expression in vivo at P22 (Fig.
5A) compared with controls, whereas nanos2 expression was not affected (Fig. 5C). Blocking
the activity of VEGFA165b isoforms (P < 0.05) increased nanos2 and neurog3 expression when
compared with controls and anti-VEGFA164 groups at P22, respectively (Fig. 5, D and F). These
data indicate that a balance between VEGFA isoform signal transduction may function to
regulate the cell fate decisions of SSC to either self-renew or differentiate.

VEGF isoforms regulate in vivo SSC homeostasis after germ cell transplantation
analysis
Germ cell transplantation analysis was used to determine the effect of VEGFA isoform
treatments from P3–P5 on SSC formation at P8 and subsequent proliferation of the adult SSC
population at P22. To accomplish this goal, testis tissue from VEGFA isoform and antibodytreated Rosa26+ mice were obtained at P8 and P22 and digested to obtain a single-cell
suspension of germ cells for transplantation into the testis of infertile, busulfan-treated recipient
mice (Fig. 6). Eight weeks after transplantation, recipient mice were killed, testes collected and
stained with 5-bromo-4-chloro-3-indoyl β-d-galactoside, and the number of blue, donor-derived
stem cell colonies was recorded (Fig. 6, A and B). In addition to calculating the number of SSC,
we also assayed the postcolonization expansion rate of our donor-derived SSC to determine the
effect of treatment on SSC self-renewal at P8 and maturation at P22, respectively (Fig. 6, C and
D).
Germ cells obtained from VEGFA164-treated mice contained the same number of SSC as controls
at P8 and P22, respectively (Fig. 7A). In contrast, in vivo VEGFA165b treatment significantly
decreased the colonization efficiency of SSC, as evidenced by a 2-fold or greater reduction in
donor-derived colonies detected at P8 and P22 (P ≤ 0.05), when compared with control and
VEGFA164 treatments (Fig. 7A). Interestingly, donor germ cells harvested at P8 from mice
treated with antibodies against VEGFA164 and VEGFA165b contained significantly less SSC than
controls after 8 wk transplantation (Fig. 7B). However, a compensatory increase in the number
of SSC obtained from mice treated with anti-VEGFA164 was detected by P22, based on the
number of donor-derived colonies observed after transplantation (Fig. 7B). In contrast, the
number of SSC in donor mice injected with anti-VEGFA165b remained significantly lower (P ≤
0.05) than control and anti-VEGFA164-treated mice, respectively (Fig. 7B). These data indicate
that VEGFA164 may be critical for SSC formation and self-renewal, whereas VEGFA165b likely
regulates SSC differentiation and/or survival.
Analysis of colony expansion demonstrated that VEGFA165b treatment decreased, whereas
blocking VEGFA165b significantly increased the growth and expansion rate of P8 donor SSC
when compared with controls and anti-VEGFA164 groups (Fig. 7, C and D). Conversely, donor
SSC harvested from P22 mice treated with VEGFA164 demonstrated reduced colony growth

following transplantation when compared with vehicle alone (Fig. 7C). Interestingly, blocking
the activity of VEGFA165b produced similar effects in P22 donor SSC, evidenced by a 3-fold
decrease in colony growth and expansion in reference to controls (Fig. 7D). This disparity
suggests that a balancing act between VEGFA isoform signaling functions to regulate the cellfate decisions of SSC in vivo. The results of transplantation indicate diverse roles for VEGFA
isoform activity with respect to regulating SSC homeostasis in vivo.

Discussion
VEGFA, known for its role as a potent endothelial cell mitogen (22), has been implicated in a
variety of nonvascular processes including neurogenesis (39–44), myogenesis (45–47), granulosa
cell function (48–50), and testis development (15, 17, 51, 52). In humans, the VEGFA gene spans
16,272 bp of chromosome 6p12 and consists of eight exons (19). Alternative splicing of VEGFA
yields proangiogenic isoforms (VEGFA111, VEGFA121, VEGFA145, VEGFA162, VEGFA165,
VEGFA183, or VEGFA206) and antiangiogenic isoforms (VEGFA121b, VEGFA145b, VEGFA165b,
VEGFA183b, or VEGFA189b) in regard to vascular development (19), but the role of these
isoforms in nonvascular processes have yet to be elucidated. Accordingly, the complexity of
VEGFA signal transduction in vivo increases because each of the 14 known VEGFA splice
variants vary slightly in terms of biological activity, mechanism of receptor activation, and
binding affinity for receptor/coreceptor interactions despite overlapping expression within a
given cell type (19, 22, 32, 53–58).
Recent studies have found that SSC self-renewal, proliferation, and differentiation depend on the
contributions of extrinsic and intrinsic factors modulated through the somatic cell niche (8).
Identification of the network of factors regulating the biological activity of SSC is difficult due
to the lack of specific SSC markers. As a result, in vivo treatment and transplantation studies are
critical for a better understanding of the underlying mechanisms directing SSC cell fate.
In this study, we used qRT-PCR and immunohistochemical analysis to demonstrate the age- and
cell-specific expression of the major VEGFA family ligands and receptors that coincide with
specific events critical for germ cell development. The pattern of ligand expression we observed
supports the hypothesis that autocrine and paracrine VEGFA production by germ and Sertoli
cells is important for regulating SSC proliferation, self-renewal, and differentiation. Just as
importantly, these ligands elicit their effects after binding to receptors FLT1 and KDR and the
cofactor NRP1 in endothelial (22, 24, 57, 59–63) and nonvascular (37, 41, 44, 46, 49, 64–68) cell
types. We demonstrate here differential expression of these receptors in gonocytes,
undifferentiated spermatogonia, and Sertoli cells within the seminiferous epithelium during
postnatal development. Due to the complex cell biology of the testis and activity of VEGFA
isoforms, we also characterized the cell types affected by VEGFR signaling in situ, using
phosphorylation-specific antibodies against the major intracellular kinase-active domains of
FLT1, KDR, and NRP1. We observed robust FLT1 signal transduction in mitotically inactive
and migrating gonocytes shortly after birth, implicating its inherent role in regulating gonocyte
survival, proliferation, and migration. In contrast, strong KDR and NRP1 activation was
restricted to proliferating gonocytes and undifferentiated spermatogonia present on the basement
membrane from P3–P8, and NRP1 activation appears to be restricted to a small population of
undifferentiated spermatogonia from P14 to adulthood. The Sertoli cell pattern of FLT1, KDR,

and NRP1 activation correlates well with the differential expression of VEGFA ligands observed
and, together with our germ cell data, support the hypothesis that VEGFA isoforms regulate SSC
either directly or in concert with somatic niche cells.
Thus, we hypothesized that VEGFA family isoforms play an important role in regulating the cell
fate decisions of SSC and used functional transplantation to test the effects of VEGFA164 or
VEGFA165b, the two most potent pro- and antiangiogenic variants, on SSC self-renewal and
differentiation in vivo. Based on colony number and growth rate after ligand and antibody
treatment, we conclude that proangiogenic VEGFA164 supports SSC proliferation and selfrenewal in mice, extending our findings in bulls (17). In contrast, when donor mice are treated
with VEGFA165b, their SSC have a reduced capacity for proliferation and self-renewal.
Similarly, treatment with VEGFA165b results in a larger number of spermatogonia present,
demonstrating that VEGFA165b has a role in stimulating SSC differentiation to produce
spermatogonia. Blocking VEGFA165b activity in mice resulted in a peculiar phenotype
characterized by substantial loss of undifferentiated germ cells in situ and a smaller adult SSC
population compared with controls. Thus, VEGFA165b signaling may also elicit a cytoprotective
response in germ cells, similar to findings in the retinal epithelial cells (69). These data
demonstrate VEGFA isoform regulation of SSC homeostasis likely requires a balancing act
between proangiogenic and antiangiogenic variants. We recognize the potential for VEGFA
treatments to elicit systemic effects on gonadotropin levels, such as FSH, that may modulate
somatic cell populations. However, this is unlikely because no difference in Sertoli cell number
was observed at any time points in the present study. Alteration of VEGFA isoform production
from angiogenic to antiangiogenic isoforms could shift SSC from self-renewal to differentiation.
These findings may have implications associated with accelerated loss of sperm production due
to loss of SSC or precocious SSC differentiation. Investigation of cell-specific mechanisms that
regulate alternative splicing in the testis and the specific mechanisms by which VEGFA
treatment affects SSC fate decisions will be the focus of future in vitro studies.
Several studies have demonstrated the importance of GDNF for maintaining SSC survival and
self-renewal (9, 10, 70) via activation of ret proto-oncogene (RET)Y1062 signaling (71). This is
intriguing because GDNF expression appears to be weak in the postnatal testis in vivo based on
publicly accessible microarray datasets (72) and is expressed in both germ and somatic cells in
the seminiferous tubule (8). Interestingly, VEGF signaling has been shown to cross talk with the
GDNF pathway in the developing kidney by inducing RETY1062 phosphorylation and upregulation of GDNF expression (73) in a pattern suggesting a positive feedback loop exists for
these growth factors. These observations, along with the pattern of VEGFA isoform and receptor
expression by germ and somatic niche cells, suggest an intricate, multifactor network supporting
the maintenance of SSC and the initiation of spermatogonia differentiation. To our knowledge,
this is the first report of active VEGFR signaling detected in male germ cells, and more
importantly, functional transplantation of SSC demonstrates that VEGFA isoforms regulate the
cell fate decisions of SSC in vivo. The functional roles VEGFA splice variants and the complex
partnerships between receptors leading to regulating the biological activity of SSC will be the
focus of future experimentation.
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Footnotes
Abbreviations:
DDX4
DEAD (Asp-Glu-Ala-Asp) box polypeptide 4
FLT1
fms-related tyrosine kinase 1
GDNF
glial cell line-derived neurotrophic factor
KDR
kinase insert domain receptor
NRP1
neuropilin 1
P1.5
postnatal d 1.5
qRT-PCR
quantitative real-time RT-PCR
RET
ret proto-oncogene
SSC
spermatogonial stem cells
VEGFA
vascular endothelial growth factor A
VEGFR
VEGFA receptor.
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Figures and Tables
Table 1.
TaqMan PCR probes used for quantitative real-time RT-PCR assays
Assay ID
Gene symbol
Gene name
Mm00455914_m1 Bcl6b
B-cell CLL/lymphoma 6 member B protein
Mm01210866_m1 Flt1
Fms-related tyrosine kinase 1
Mm00599849_m1 Gdnf
Glial cell line-derived neurotrophic factor

Assay ID
Gene symbol
Gene name
Mm00833897_m1 Gfra1
Glial cell line-derived neurotrophic factor family receptor α1
Mm01222419_m1 Kdr
Kinase insert domain receptor
Mm02525720_s1 Nanos2
Nanos homolog 2
Mm00437606_s1 Neurog3
Neurogenin 3
Mm00435379_m1 Nrp1
Neuropilin 1
Mm00803099_m1 Nrp2
Neuropilin 2
Mm00475529_m1 Rps2
Mitochondrial ribosomal protein S2
Mm00437304_m1 Vegfa
VEGFA

Table 2.
List of antibodies used for immunohistochemical analysis
Antigen
Antigen description
Dilution Source
DDX4
Rabbit polyclonal to human DDX4/MVH
1:500 Abcama
FLT1
Rabbit polyclonal to mouse FLT1 (C-17)
1:400 SCBTb
KDR
Mouse monoclonal to human KDR (A-3)
1:400 SCBTb
NRP1
Rabbit monoclonal to human NRP1 (EPR3113)
1:200 Abcama
NRP2
Rabbit monoclonal to human NRP2 (ab39067)
1:200 Abcama
VEGFA164 Rabbit polyclonal to mouse VEGFA (A-20)
1:200 SCBTb
VEGFA165b Mouse monoclonal to human VEGF 165b (MRVL56/1) 1:200 Abcama
a
Abcam, Inc., Cambridge, MA.
b
Santa Cruz Biotechnology, Santa Cruz, CA.

Fig. 1.

Expression of VEGFA family isoforms, receptors, and coreceptors in mouse testes. Quantitative
measurement (real-time RT-PCR) of mRNA of Vegfa (A), Flt1, (B) Kdr, (C), Nrp1, (D) and
Nrp2 (E) from birth to adulthood. Data are representative of three independent experiments (n =
3), and different letters indicate significant differences between means (P < 0.05).

Fig. 2.

VEGFA isoforms are expressed by germ and somatic cells during testis development.
Immunohistochemical analysis of VEGFA164 (D–F) and VEGFA165b (G–I), protein expression in
the testis tissue of P3, P5, and P8 mice. Omitting primary antibody served as a negative control
in testis tissue (A–C). Four donors were used for each age and antigen evaluated. Scale bars, 50
μm.

Fig. 3.

VEGFA isoforms regulate mouse testis development in vivo. A, Diagram of the treatment
schedule for experiments; B, testis weights of mice after VEGFA164, VEGFA165b, and control
treatments; C, testis weights of mice after antibody treatments to block the biological activity of
VEGFA164 and VEGFA165b in addition to treatment with nonspecific IgG as a control. Data are
representative of at least three independent experiments (n ≥ 3), and different letters indicate
significant differences between means (P < 0.05).

Fig. 4.

VEGFA isoforms regulate the biological activity of undifferentiated germ cells in vivo. Effect of
VEGFA isoform ligand (A) and antibody (B) treatments daily from P3–P5 on the number of
germ cells present in the testes of P8 and P22 mice. VEGFA isoform ligand (C) and antibody (D)
treatments daily from P3–P5 on spermatogonial numbers present in the testes of P8. Germ cells
were identified and counted with the use of immunohistochemical localization of DDX4, a germ
cell-specific marker. E and F, Representative images of DDX4-stained testis tissue in P8 (E) and
P22 (F) mice, respectively. Data are representative of three independent experiments (n = 3), and
different letters indicate significant differences between means (P < 0.05). Scale bars, 50 μm.

Fig. 5.

Effect of VEGFA isoform ligand (A, C, and E) and antibody (B, D, and F) treatments daily from
P3–P5 on the expression of SSC niche-associated factors in P8, P12, and P22 mice, respectively.
A–F, The normalized, mean expression values of Bcl6b (A and B), Nanos2 (C and D), and
Neurog3 (E and F). Data are representative of at least three independent experiments, and
different letters indicate significant differences between means (P < 0.05).

Fig. 6.

Representative images of recipient testes 8 wk after cell transplantation used to assay the effects
of VEGFA ligand and antibody treatments daily from P3–P5 on regulating the biological activity
of donor SSC. Light micrographs of recipient testes 8 wk after transplantation with SSC colony
formation as indicated by areas of blue staining. A, Representative recipient testis with SSC
colonization and donor-derived spermatogenesis after transplantation of germ cells at P8 after
VEGFA165b treatment from P3–P5 in the donor mouse. Note the limited number of blue areas
representing SSC colonization; B, representative recipient testis with SSC colonization after
transplantation of germ cells at P8 after VEGFA164 treatment from P3–P5 in the donor mouse; C,
a representative seminiferous tubule from a recipient testis with low rate of SSC expansion such
as observed in the recipient testes transplanted with donor germ cells at P8 after VEGFA165b
treatment; D, a representative seminiferous tubule from a recipient testis with a high rate of SSC
expansion such as observed in the recipient testes transplanted with germ cells from P8 donor
mice treated with the anti-VEGFA165b antibody. Data are representative of at least four
independent experiments (n ≥ 4), and different letters indicate significant differences between
means (P < 0.05). Scale bars, 0.5 mm (all panels).

Fig. 7.

Effect of VEGFA family isoforms on colonization efficiency of donor-derived SSC originating
from mice treated from P3–P5 and transplanted at either P8 or P22. Recipient testes were
analyzed 8 wk after transplantation. A, SSC colony number in testes of recipient mice after
VEGFA164, VEGFA165b, or control treatment; B, SSC colony number in testes of recipient mice
after anti-VEGFA164 antibody, anti-VEGFA165b antibody treatment, or treatment with
nonspecific IgG control; C and D, SSC colony growth and expansion after VEGFA164,
VEGFA165b, or control treatment (C) and SSC colony growth and expansion after antiVEGFA164 antibody, anti-VEGFA165b antibody treatment, or treatment with nonspecific IgG
control (D). Data are representative of at least three independent experiments, and different
letters indicate significant differences between means (P < 0.05).
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